Icosavax Announces $67.8 Million Registered Direct Offering of Common Stock

May 22, 2023

https://www.globenewswire.com/news-release/2023/05/22/2673849/0/en/Icosavax-Announces-67-8-Million-Registered-Direct-Offering-of-Common-Stock.html

SEATTLE, May 22, 2023 (GLOBE NEWSWIRE) — Icosavax, Inc. (Nasdaq:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 8,369,754 shares of its common stock at a purchase price of $8.10 per share. The financing was led by new investor TCGX with participation by additional new investors including Logos Capital and Vivo Capital. All of the shares are to be sold by Icosavax. Icosavax expects to receive gross proceeds of approximately $67.8 million from the offering.

Read more at globenewswire.com

Related news for (ICVX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.